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Abstract
Background
Several studies have reported that metformin can reduce the risk of hepatocellular carcino-
ma (HCC) in diabetes patients. However, the direct anti-HCC effects of metformin have
hardly been studied in patients, but have been extensively investigated in animal models of
HCC. We therefore performed a systematic review and meta-analysis of animal studies
evaluating the effects of metformin on HCC.
Methods
We collected the relevant studies by searching EMBASE, Medline (OvidSP), Web of Sci-
ence, Scopus, PubMed Publisher, and Google Scholar. Studies were included according to
the following inclusion criteria: HCC, animal study, and metformin intervention. Study quality
was assessed using SYRCLE’s risk of bias tool. A meta-analysis was performed for the out-
come measures: tumor growth (tumor volume, weight and size), tumor number and
incidence.
Results
The search resulted in 573 references, of which 13 could be included in the review and 12
included in the meta-analysis. The study characteristics of the included studies varied con-
siderably. Two studies used rats, while the others used mice. Only one study used female
animals, nine used male, and three studies didn’t mention the gender of animals in their ex-
periments. The quality of the included studies was low to moderate based on the assess-
ment of their risk of bias. The meta-analysis showed that metformin significantly inhibited
the growth of HCC tumour (SMD -2.20[-2.96,-1.43]; n=16), but no significant effect on the
number of tumors (SMD-1.05[-2.13,0.03]; n=5) or the incidence of HCC was observed (RR
0.62[0.33,1.16]; n=6). To investigate the potential sources of significant heterogeneities
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found in outcome of tumor growth (I2=81%), subgroup analyses of scales of growth mea-
sures and of types of animal models used were performed.
Conclusion
Metformin appears to have a direct anti-HCC effect in animal models. Although the intrinsic
limitations of animal studies, this systematic review could provide an important reference for
future preclinical animal trials of good quality and clinical development.
Introduction
Hepatocellular carcinoma (HCC) is the fifth most prevalent cancer worldwide and the third
leading cause of death from cancer. Surgical resection and liver transplantation are the only po-
tentially curative treatment for a small proportion of the patients. However, disease recurrence
hampers the ultimate success of the treatment [1]. Sorafenib, an oral multikinase inhibitor, was
approved to treat advanced HCC. This however only increases patient survival with approxi-
mately 2–3 months [2,3]. Therefore, it is necessary to explore new strategies to improve the
management of HCC.
Metformin is an oral drug widely used for treatment of type II diabetes. Interestingly, several
studies, including observational studies and some randomized controlled trials (RCT), have re-
ported that metformin can affect the risk of hepatocellular carcinoma (HCC) in diabetic pa-
tients [4–6]. Although these studies have suggested a preventive effect of metformin on the risk
of HCC in these diabetic patients, there is still lacking of investigation whether metformin has
direct anti-tumor effect in HCC patients. Nevertheless, substantial research has been per-
formed in animal models of HCC, although the data are still inconclusive. Meta-analyses on
data from animal studies can be used to explain clinical observation and to inform clinical
trial design.
To better understand the direct effects of metformin on HCC and to pave the way for fur-
ther prospective clinical study, we performed a systematic review and meta-analysis of current-
ly available data from HCC animal models treated with metformin.
Materials and Methods
Review protocol
A protocol for this systematic review was prepared using SYRCLE’s protocol format (https://
www.radboudumc.nl/Research/Organisationofresearch/Departments/cdl/SYRCLE/Pages/
Protocols.aspx) [7].
Literature search
A systematic search (conducted on July 2014, without any restrictions on publication data or
language) was conducted in Medline (OvidSP), Embase.com, Web of Science, and Scopus. Ad-
ditional referenes were retrieved from Google Scholar, and unindexed references from
PubMed. The searches were designed and executed by an experience information specialist
(WB). The search strategy consisted of two main components: hepatocellular carcinoma, and
metformin, and results were limited to animal studies. For each element multiple synonyms
were searched in title and/or abstract, and when available thesaurus terms (Mesh for medline
and Emtree for embase). The full strategy is available in S1 Table.
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Study selection and inclusion criteria
The selection procedure was performed by two independent reviewers (J.L. and P.H.). The ex-
clusion criteria for the title and abstract screening phase include: 1). not primary study; 2). not
animal study; 3). not disease of interest (HCC), 4). not intervention of interest (metformin).
The following additional criteria were used for full-text screening: 1). full-text not available; 2).
double publication; 3). conference abstracts. In case of disagreement between the reviewers,
consensus was reached.
Study characteristics and data extraction
Data was extracted from the full-text papers of the studies. The following items were extracted:
author, year, language, species/strain, description of control group, animal gender, age and
weight, number of animals in control and experimental group, the method for the establish-
ment of the animal models, metformin dosage, timing, duration and route of metformin ad-
ministration, and outcome measures (Table 1).
The outcome measures including HCC growth, number and incidence were included in the
meta-analysis. Mean value, standard deviation (SD) and the number of animals per group were
extracted. If relevant data were not available in the text but only presented in graphic form, ob-
taining the data by measuring the graphs using Universal Desktop Ruler (Universal On-screen
Digitizer, AVPSoft.).
Quality assessment of included studies
The SYRCLE’s Risk of Bias tool was used to assess the risk of bias of all included studies [8].
Two independent investigators (J.L. & P.H.) performed quality assessment of all included stud-
ies. Disagreements were resolved by discussion.
Data synthesis and statistical analysis
For the outcome measures of HCC growth and number, the standardized mean difference
(SMD) was used as the effect measure. For the outcome measure of HCC incidence, Risk Ratio
(RR) was used.
If studies contained multiple independent groups (e.g. different animal models or different
time points), they were treated as separate experiments.
Because of expected heterogeneity, the statistical model of analysis used in this meta-analy-
sis was a random effects model. I2 was used as a measure of heterogeneity. In order to explore
potential causes of heterogeneity, predefined subgroup analyses were conducted for tumor vol-
ume, weight and size.
With assistance of RevMan5.3 (Cochrane Library) software, Forest Plots were established.
In addition, sensitivity analyses were conducted as to evaluate whether the findings were robust
enough to the decisions made. Visual inspection of funnel plots was used to detect publication
bias. Our procedures accorded with PRISMA guidelines for reporting systematic review/meta-
analysis (S2 Table).
Results
Description of the included studies
The comprehensive search strategy on the effects of metformin on HCC in animal models re-
sulted in 573 records. After duplicates were removed, 340 studies were left. After title and ab-
stract screening, 21 studies were screened full text. Ultimately, 13 studies were included in our
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systematic review [9–21], of which 12 studies (total 29 animal experiments and 311 animals in-
volved) could be included in the meta-analysis (fig 1) [9–20].
The characteristics of all included studies are described in Table 1. Since the investigation of
metformin on HCC using animal models has only been started in recent years, the publication
dates of the included studies ranged from 2012 to 2014. Apart from these, the characteristics
among these studies varied considerably. The characteristics of animals themselves differed
substantially between the studies. Seven of the studies used BALB/c nude mice, and others used
C57BL/6J mice, NOD/SCID mice, HBxTg mice, and Wistar rat. Among these studies, seven
used a subcutaneous xenograft model, while others used oncogenic compound inducing mod-
els. Only half of the studies used the same dosage of metformin (250 mg/kg). Administration
timing and duration of metformin varied greatly. Besides, various time-points for outcome
measurements were mentioned in the studies.
Risk of bias and quality of included studies
Fig 2 shows the results of the risk of bias assessment of the 13 studies included in this systemat-
ic review. Based on this assessment, 7 (54%) of the studies stated that the allocation was ran-
domized. Since the background of animals were essentially homogenous, most of the studies
didn’t describe the method of randomization. Besides, none of the studies mentioned whether
the allocation was adequately concealed. As shown clearly in Fig 2, many items were scored as
“unclear”, which indicates that reporting—and presumably experimental design—of these ani-
mal studies can be improved.
Overall analysis of the effects of metformin on HCC growth
Ten out of the twelve studies reported outcomes related to tumor growth (tumor volume, tumor
size or tumor weight). These 10 studies contained 18 independent experiments [9–12,15–20].
Of these 18 experiments, 12 showed a significant decrease of tumor growth. None of the experi-
ments showed a significant increase of tumor growth. Meta-analysis of these experiments re-
vealed that metformin intervention had a significant inhibiting effect on HCC growth (SMD-
2.20[-2.96, -1.43]; n = 18) (Fig 3A). However, heterogeneity was quite high (I2 = 81%).
Subgroup analysis
To determine whether the effects differed per scale of measurement, the clinically relevant out-
come measures including “tumor volume”, “tumor weight” and “tumor size” were analyzed
separately in subgroups. As displayed in Fig 3B, even though all three subgroups showed a sta-
tistically significant inhibition of growth, the effect on volume (SMD-3.11[-4.36, -1.87]; n = 10)
seemed to be larger than on size (SMD-0.69[-1.18, -0.20]; n = 4). Besides, heterogeneity levels
significantly decreased in the subgroup analysis of “tumor size”(I2 = 0.0%) while still high het-
erogeneity level were observed in subgroups of “tumor volume”(I2 = 82%) and “tumor
weight”(I2 = 84%).
In addition, a subgroup analysis was performed for the types of HCC model used. This anal-
ysis demonstrated that metformin had significant effect on both xenograft (SMD-2.77[-3.74,
-1.79]; n = 14) and non-xenograft model (SMD-0.69[-1.18, -0.20]; n = 4), but the former group
seemed to be affected by metformin more than the latter group. Subgroup analysis of “non-
xenograft model” clearly reduced heterogeneity (I2 = 0.0%), while “xenograft model” subgroup
analysis did not change high heterogeneity level.
HCC Inhibition by Metformin in Animals
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Fig 1. Flow diagram showing literature search and selection results.
doi:10.1371/journal.pone.0127967.g001
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Effects of metformin on HCC number
In addition to the analysis of the effect on tumor growth, we also did analysis on HCC number
in five animal experiments. Of these five experiments, four showed a significant decrease of
HCC number and none showed a significant increase. Although it was unclear how the data
were presented in DePeralta’s study [14], we assumed they were presented as mean ± SE. The
result didn’t show significant inhibitory effect on HCC tumor number by metformin (SMD-
1.05[-2.13,0.03]; n = 5) (Fig 4). We found high heterogeneity (I2 = 78%).
Effects of metformin on HCC incidence
The effects of metformin on the incidence of HCC in animal models was evaluated. Only two
studies showed a significant decrease of HCC incidence; whereas the others showed trend of
decrease but one showed a trend of increase. However, the meta-analysis didn’t show a signifi-
cant effect of metformin on the incidence of HCC in comparison with non-treatment group
(RR 0.62[0.33,1.16]; n = 6) (Fig 5). The heterogeneity was high (I2 = 83%).
Sensitivity analysis
We performed sensitivity analysis to assess the robustness of our results on the effects of met-
formin on HCC number. In the subgroup analysis of “tumor number”, we assumed that
DePeralta[14]presented the data as mean ± SE. For this sensitivity analysis we test the
Fig 2. Risk of bias, score (%) per risk of bias item. Yes = low risk of bias, no = high risk bias,? = unclear risk of bias.
doi:10.1371/journal.pone.0127967.g002
HCC Inhibition by Metformin in Animals
PLOS ONE | DOI:10.1371/journal.pone.0127967 June 1, 2015 7 / 13
assumption that the data were presented as mean ± SD. With this assumption the meta-
analysis showed that metformin could significantly reduce HCC tumor number (SMD-1.21
[-2.29, -0.13];n = 5). This result differs from our previous findings in the subgroup analysis. In-
terpretation of this outcome measure should be done with extreme caution, as current available
evidence is still inconclusive.
Fig 3. Effects of metformin on tumor growth in HCC animal models. (A) Forest plot and (B) subgroup analysis of the 16 included studies. The forest plot
displays the SMD, confidence interval, and effect weight for each study, plus the pooled effect estimate & confidence interval.
doi:10.1371/journal.pone.0127967.g003
Fig 4. Effects of metformin on tumor number in HCC animal models.
doi:10.1371/journal.pone.0127967.g004
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Publication bias
Publication bias was assessed for the outcome of overall tumor growth, since the analysis of
this outcome included the highest number of studies. On visual inspection of the funnel plot
(Fig 6), small studies with no or a negative effect seem to be missing. This asymmetry might in-
dicate the presence of publication bias.
Discussion
Although there were already several clinical studies evaluating the effects of metformin on
HCC risk in human population, all of them were on the chemo-preventive effect by metformin
rather than the therapeutic effect and, moreover, the population were all diabetic patients. A
meta-analysis of the effects of anti-diabetic medications on the HCC risk, in which both obser-
vational and RCT studies were included, has suggested a half reduction in HCC incidence
when using metformin treatment [22]. However, our meta-analysis systematically analyzed all
relevant animal studies to assess the therapeutic potential of metformin against HCC.
In this comprehensive systematic review and meta-analysis, we analyzed and described the
effects of metformin on HCC growth and incidence. The overall analysis of the effect of growth
showed that use of metformin was associated with a significant inhibitory effect (SMD = -2.20
±0.76) on HCC growth, compared to untreated group. This therapeutic effect remained stable
across subgroups of tumor volume, tumor weight and tumor size. It was most pronounced in
“tumor volume”measurement while least in “tumor size”measurement. Besides, we performed
subgroup analysis under the “tumor growth”. Both xenograft and non-xenograft studies
showed significant inhibitory effect of metformin on HCC growth.
Mechanism underlying metformin anti-HCC
The anti-cancer effect of metformin was speculated to be associated with the activation of
adenosine monophosphate-activated protein kinase (AMPK). An important upstream kinase
of AMPK is LKB1, an very important tumor suppressor [23,24]. This signaling pathway was
also discussed and explored in the included HCC animal trials. The coexistence of AMPK-
dependent and AMPK-independent mechanisms for the effects of metformin on cancer was
proposed[9,10,12,15]. But we should keep in mind of different study methodologies. For
Fig 5. Effects of metformin on tumor incidence in HCC animal models.
doi:10.1371/journal.pone.0127967.g005
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instance, two studies used cell lines in vitro[9,15]; one study used tumor harvested from xeno-
graft[10]; whereas one study demonstrated their result based on observing AMPK level in liver
[12]. In addition, metformin may also inhibit HCC cell growth by regulating cell-cycle regula-
tory proteins, such as cyclin D1 and cyclin E [10,14]. Of particular note, c-myc was suggested
as a critical mediator in hepatocarcinogenesis [25]. Metformin treatment has been shown to in-
hibit c-myc expression by up-regulating let-7 family (tumor suppressor) [11]. However, no
study among the included animal studies discussed such mechanism underlying specific HCC
stage. Although we found one human study relevant to early stage of HCC, no clear mechanis-
tic insight of metformin on early stage HCC was described[26].
Side effects of metformin in animal models
Being a classic antidiabetic medication, metformin is widely used among patients because of its
relatively low cost and high safety profile. 10 out of 13 studies included in this systematic re-
view mentioned tolerability of metformin treatment. These studies consistently showed that
metformin didn’t change body weight and serum glucose level of animals. However, it should
also be taken into consideration of further investigation on the appropriate therapeutic dosage
Fig 6. Funnel plot overseeing publication bias of included studies.
doi:10.1371/journal.pone.0127967.g006
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rang of metformin for anti-cancer treatment. Evaluation of safety with these particular dosages
is very necessary, especially when metformin is applied in non-diabetic patients.
Limitations
By using the risk of bias tool, we found out that reporting is poor and therefore the methodo-
logical quality of many studies is unclear. It shows that there is much room for improvement,
since many items were shown “unclear” and only a few items were shown low risk only in very
few studies. Besides, by visualizing the funnel plot, publication bias seems also to be present,
probably due to the missing of studies with no or negative effects. Actually, in total, only 12
studies were included in the meta-analysis. Both the unclear methodological quality and publi-
cation bias might lead to under or overestimation of the overall effect size of metformin effect
on anti-HCC, which is an additional threat to the robustness of the data especially the ones
that are already inconclusive. What’s more, high heterogeneity was also seen among the stud-
ies, which is common in animal studies, although we tried to explore the potential factors con-
tributing the heterogeneity. All of these potential limitations might influence us to draw
concrete conclusions on the anti-HCC effect of metformin.
Besides, there were some methodological issues which might influence the translation of an-
imal results to human trials. Firstly, the literature is unclear about which animal method is
most representative for patient HCC. We found various HCC methods used in these studies:
xenograft, DEN-induction, transgenic and dietary models. Secondly, there are two different ad-
ministration routes (oral or i.p.) of metformin in the studies. However, metformin is usually an
orally administrated drug in clinic, raising the question whether administration method could
also affect the effect of metformin on tumor.
HCC invasion and metastasis are crucial factors related to poor prognosis. However, none
of the animal studies described if metformin had potential effect on HCC metastasis, except
one study indirectly mentioned correlation of metformin/p-AMPK with distant metastasis in
human HCC cohort study [19].
Another limitation is that these animal studies did not study the HCC stage indicated for
metformin. HCC stage could be an important factor for the therapeutic efficacy of metformin
and has implication for selecting appropriate candidates for metformin treatment. Therefore,
it’s very necessary to take the stage of HCC into account in the experimental design. As for xe-
nograft animal model, which were used in most of the studies, however, it’s hard to define the
cancer stage which didn’t discuss in the studies. In addition, although it’s possible to identify
tumor stage in spontaneous animal tumor model, the authors did not report any information
about HCC stage in their animal study[12,17].
Implications for practice
Based on the results of this meta-analysis, metformin could potentially have a therapeutic effect
on HCC. Besides, the maximal dose of metformin used in all the included animal studies were
consistent with human therapeutic dose in diabetics according to the calculation [10]. This fur-
thermore supported the reliable and applicable results from animal models. Although several
clinical studies reported that metformin could negatively modify the risk of HCC in diabetic
patients [4–6], there are not yet any clinical trial investigating the therapeutic effect of metfor-
min on HCC. Currently, several ongoing clinical trials (www.clinicaltrials.gov) are evaluating
the effects of metformin on different cancers (breast cancer, colorectal cancer, pancreatic can-
cer, etc.), But not for HCC. Thus, the results of this systematic review provide an important ref-
erence for the future preclinical animal trials with high quality to aid the development of
metformin for anti-HCC treatment in clinical trials. Considering the dominant risk factor for
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HCC in many western countries in particular United States–obesity and metabolic syndrome,
metformin would be an appropriate choice for such a high-risk of population of HCC.
Conclusion
In summary, this systematic review of animal studies suggests that metformin potentially has a
direct inhibitory effect on HCC growth, although the effects on tumor number and incidence
are inconclusive. It supports the clinical observation that metformin is associated with lower
risk of HCC in diabetic patients. Although these animal studies have some intrinsic limitations,
these results do provide an important reference for future high-quality preclinical animal trials
and potential clinical development.
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